Peregrine Pharmaceuticals Inc (PPHM)

0.37
0.00 0.62
NASDAQ : Health Care
Prev Close 0.37
Open 0.37
Day Low/High 0.37 / 0.38
52 Wk Low/High 0.29 / 1.32
Volume 698.23K
Avg Volume 1.62M
Exchange NASDAQ
Shares Outstanding 241.46M
Market Cap 89.34M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

In trading on Thursday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 15% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $17.22 on the day. As of last close, PPHMP was trading at a 29.60% discount to its liquidation preference amount.

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

In trading on Wednesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 15% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $17.15 on the day. As of last close, PPHMP was trading at a 29.00% discount to its liquidation preference amount.

Peregrine Pharmaceuticals Announces Formal Commissioning Of New, State-of-the-Art Commercial Manufacturing Facility

Peregrine Pharmaceuticals Announces Formal Commissioning Of New, State-of-the-Art Commercial Manufacturing Facility

-- Facility Being Operated by Avid Bioservices Subsidiary With Capacity to Potentially Generate Additional $40 Million in Annual Revenue --

Peregrine Pharmaceuticals Provides Update On Phase III SUNRISE Trial Of Bavituximab

Peregrine Pharmaceuticals Provides Update On Phase III SUNRISE Trial Of Bavituximab

Conference Call With Management Scheduled for 4:30 p.m. Eastern Time

First Week of October 21st Options Trading For Peregrine Pharmaceuticals (PPHM)

First Week of October 21st Options Trading For Peregrine Pharmaceuticals (PPHM)

Investors in Peregrine Pharmaceuticals Inc. saw new options begin trading this week, for the October 21st expiration.

Peregrine Pharmaceuticals And National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration To Evaluate Novel Cancer Treatment Combinations With Bavituximab

Peregrine Pharmaceuticals And National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration To Evaluate Novel Cancer Treatment Combinations With Bavituximab

NCCN Alliance Includes 26 Leading Cancer Centers and World-Class Thought Leaders on Innovative Cancer Combination Therapies

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 12% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 12% Yield Mark

In trading on Tuesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 12% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $21.59 on the day. As of last close, PPHMP was trading at a 12.40% discount to its liquidation preference amount.

AstraZeneca And Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration To Include Phase II Lung Cancer Combination Clinical Trial

AstraZeneca And Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration To Include Phase II Lung Cancer Combination Clinical Trial

- Global, Randomized Phase II Trial to Evaluate Immunotherapy Combination of Peregrine's PS-Targeting Bavituximab and AstraZeneca's PD-L1 Inhibitor Durvalumab (MEDI4736) in Previously Treated NSCLC -

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 11.5% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 11.5% Yield Mark

In trading on Friday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 11.5% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $22.32 on the day. As of last close, PPHMP was trading at a 5.44% discount to its liquidation preference amount.

Peregrine Pharmaceuticals Series E Convertible Preferred Stock About To Put More Money In Your Pocket

Peregrine Pharmaceuticals Series E Convertible Preferred Stock About To Put More Money In Your Pocket

On 9/16/15, Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock will trade ex-dividend, for its quarterly dividend of $0.6562, payable on 10/1/15. As a percentage of PPHMP's recent share price of $22.49, this dividend works out to approximately 2.92%, so look for shares of PPHMP to trade 2.92% lower — all else being equal — when PPHMP shares open for trading on 9/16/15.